The realities and practicalities of drug discovery and development
Meeting Room: Rosalind Hill Room, Cristina Barrett Building, St Hilda’s College, Oxford
Registration: South Building Foyer
Date: Thursday, 24th September
The aim of the workshop is to educate and inform young and not-so-young toxinologists on the realities of drug discovery and medicines development. The workshops will be led by specialists who have extensive experience in pharmaceutical and biotechnology companies as well as in assessing drug development opportunities emerging from academic labs. Participants will have the opportunity to ‘pitch’ their project to the speakers’ panel and receive constructive comments.
>Professor Glenn King, University of Queensland, Australia
>Professor Alan Harvey, University of Strathclyde, UK
Topics and speakers
1. Introduction to toxins and drug discovery – Alan Harvey
2. Finding a meaningful target: pros and cons of molecular and functional assays – Frank Sams-Dodds
3. Finding a backable development opportunity: how to get something that is worth moving towards an approved medicine – Mike Wyllie
4. Protecting your Intellectual Property: no IP? no deal! – James Houston
Presentations by participants and suggestions on improving projects’ chances of advancing into drug development – moderator: Glenn King
About organisers and speakers:
Professor Glenn King is Professor & Group Leader at the Institute for Molecular Bioscience in Brisbane, Australia and a Principal Research Fellow of the Australian National Health & Medical Research Council. Glenn has been working on animal venoms since 1996. He has extensive experience in the discovery, production, and structural and functional characterization of venom peptides, and he is intimately aware of the issues surrounding their development as drugs and insecticides. In 2006, Glenn founded an agricultural biotechnology company, Vestaron Corporation (www.vestaron.com) that is developing spider-venom peptides discovered in the lab as bioinsecticides. Glenn’s current research is largely focussed on the development of peptide drugs for treating chronic pain, epilepsy, and stroke.
Professor Alan Harvey is a professor of pharmacology at the University of Strathclyde in Glasgow. He has had a long interest in the use of toxins and other natural products for drug discovery. This has led to several patent applications and numerous leads that are currently being followed up in different therapeutic areas.
Dr Frank Sams-Dodd is currently CEO of Willingsford Healthcare Ltd, which he co-founded; it is a medical device company developing a first-in-class medical device for use in the treatment of acute and non-healing wounds and burns. He is also Managing Partner in A Tempo Consulting, which focuses on the implementation of improved research and management strategies to improve productivity in the pharmaceutical sector. Previously, he has been Chief Scientific Advisor to Asclepios Bioresearch, a venture capital company focusing on the healthcare sector; CEO of Neurofit SAS, a pre-clinical CRO located in Strasbourg, France; Vice President of Pre-clinical Research at Bionomics Ltd., an Australian biotech company developing an oncology drug; Head of Psychopharmacology, Boehringer Ingelheim GmbH, where he was responsible for psychiatric and Alzheimer’s disease drug discovery and for establishing disease models in psychiatry (schizophrenia, anxiety and depression) and neurology (Alzheimer’s, Parkinson’s) as well as relevant side-effect models; and Director of Physiology, Amylin Pharmaceuticals, Inc., responsible for the implementation of drug screening methodologies in obesity and obesity-related disorders.
Dr Mike Wyllie is Managing Director at Global Pharma Consulting, which is a strategic planning company also providing interim management and access to EU and US funds, and assistance with preparation of start-up companies for IPOs, product and portfolio evaluations, and generation of new IP.He is also Chairman of Morvus Technology Inc, a pharmaceutical company specializing in the discovery and commercialization of novel drugs for the oncology market; Chairman of Glycomar Ltd, a marine biotechnology company specialising in glycobiology and discovery of molecules as a basis of pharmaceuticals, cosmoceutical and/or nutraceutics. Previously, he was Director Urology for Pfizer Pharmaceuticals, where he was heavily involved in regulatory filing and launch of Cardura and Viagra; responsibilities also included integration of American Medical Systems and member of Pfizer Licensing Management Committee.
Dr James Houston is Director and Principal of HHA Associates Ltd, a consulting firm that specialises in advising academic groups on IP issues and on commercialisation strategies, and is the Chairman of Scottish Intellectual Asset Management Ltd. Previously, he was the Director of Research and Innovation Services at Dundee University, responsible for the office that handled technology transfer and administration of research awards for the university, including the negotiation of commercial research contracts and the ultimate commercialisation of intellectual property: over £80 million in research business, generating about £1.5 million in royalties annually. In 1987, he was the first specialist Intellectual Property Rights Officer to be appointed at a UK university.